BBS-Bioactive Bone Substitutes (BONEH.HE) Stock Analysis & AI Equity Report
BBS-Bioactive Bone Substitutes (BONEH.HE) overview
BBS-Bioactive Bone Substitutes (BONEH.HE) stock analysis and AI equity research. For the latest completed financial year, 2023, BBS-Bioactive Bone Substitutes reported revenue of EUR 0m and operating profit of EUR -3.4m; the year-end share price was 0.46 EUR and market capitalisation was EUR 5.6m. BBS-Bioactive Bone Substitutes is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BBS-Bioactive Bone Substitutes's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-10-29. Data will be refreshed during report generation.
About BBS-Bioactive Bone Substitutes
BBS-Bioactive Bone Substitutes Oyj is a Finnish medical technology company that develops, manufactures and commercializes bioactive bone graft substitutes for orthopedic surgery. Its main product, ARTEBONE, is a ready-to-use bone-healing paste based on tricalcium phosphate and bone proteins, intended to support the treatment of bone defects and healing problems.
Generate the BBS-Bioactive Bone Substitutes report
BBS-Bioactive Bone Substitutes is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BBS-Bioactive Bone Substitutes and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.